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M. Schwartz,* D. Lorke* and G. Schaude*
Chronic exposure of rodents to high dose levels of drugs, food additives and environmental chemi-
cals frequently results in liver enlargement. Several of these compounds have been found to enhance
the incidence of liver tumors in animals briefly exposed previously to hepatocarcinogens. Accord-
ingly, it has been advanced that these agents act as tumor promoters. This contention has remained
subject of controversy following reports that these substances may also cause liver tumors in non-
carcinogen-treated rodents, particularly in those characterized by a relatively high incidence of
"spontaneous" liver tumors. Since many of these chemicals are in common use, a crucial question
would seem to be whether such effects are due to facilitation of the expression of pre-existing onco-
genic potential, i.e., to tumor promotion, or to the synergistic action of weakly carcinogenic agents.
As a result of mechanistic differences tumor promotion and syn-carcinogenesis must exhibit differ-
ent dose-time-response characteristics, and, accordingly, it should be possible, in principle, to dis-
criminate between these phenomena. However, since tumor manifestation periods in low-dose
groups frequently exceed the animals average lifespan, this approach may not always yield conclu-
sive data, unless a sensitive early marker of carcinogenic activity can be employed. There is evi-
dence that enzyme-deficient preneoplastic areas in liver can be used for this purpose. A strong
quantitative correlation between carcinogen dose, the extent of ATPase deficient areas, and the sub-
sequent appearance of tumors has now been established for a number of hepatocarcinogens. Experi-
mental data are consistent with the concept that two critical events (hits) are required for induction
of ATPase deficiency in hepatocytes. The first hit is carcinogen-dependent, whereas the second hit
would seem to be due to time-dependent event(s). Tumor-promoters, such as phenobarbital, were
found to accelerate and increase formation of preneoplastic islets. This evidence, together with
data indicating that the compound is devoid of carcinogenic potential, suggests that phenobarbital
may be operative at relatively early stages of hepatocarcinogenesis by increasing the probability of
the occurrence of the time-dependent second hit. Such effects are dose-dependent and appear to be
related to the induction of liver enlargement. The changes in hepatocellular ploidy status and atypi-
cal nuclear figures observed during phenobarbital treatment and cessation thereof, suggest that
this compound might induce abnormal redistributions of genetic material. It is postulated that these
cytological changes may result in phenotypical manifestation of recessive oncogenic information.
Introduction
Ever since the discovery that mouse skin carcino-
genesis can be enhanced by chronic application of
the skin irritant croton oil (1) and the subsequent
isolation and characterization of phorbol esters as
active components (2), tumor promoters have
proved to be useful model compounds in studies on
the nature of critical steps in chemical carcinogene-
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sis (3). In the case of tumor promotion in liver,
however, investigations have not been focused
primarily on the elucidation of stages in the car-
cinogenic process, but were more concerned with
the assessment of the toxicological significance of
tumor-promoting drugs and environmental chemi-
cals. These investigations were initiated by the ob-
servation that exposure of animals to high doses of
drugs frequently resulted in pronounced liver en-
largement (4-6), and the general significance of this
phenomenon is illustrated by a report showing that
liver enlargement may occur in approximately 75%
of chronic feeding studies with newly introducedand existing chemicals (7). Subsequent investi-
gations have revealed that although different initial
events may trigger this effect, liver enlargement is
invariably a result of a growth response to meet
increased functional demands (5, 7, 8). At the
cellular level, liver enlargement is usually
characterized by pronounced cellular hypertrophy
and polyploidisation, and to a lesser extent by
hyperplasia, i.e., cell multiplication (5, 6).
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FIGURE 1. Dose-time-response relationships of chemical carci-
nogenesis in liver: 50% tumor mortality in rats continu-
ously exposed to diethylnitrosamine (DENA), 4-dimethyla-
minoabenzene (4-DAB). N-nitrosomorpholine (NNM), and
diethanolnitrosamine (DEtN) (29-31, this laboratory, man-
uscript in preparation).
Effects of Inducers of Liver
Enlargement on
Hepatocarcinogenesis
As to the effects of inducers of liver enlargement
on liver carcinogenesis, it is now clear that two
principal effects have to be distinguished. Simulta-
neous treatment of rats with a liver carcinogen and
drugs, such as phenobarbital or DDT, leads to in-
terference with the metabolic activation and/or
inactivation of the carcinogen (9, 10), and car-
cinogenic effectiveness is nearly always diminished
(11-13). In contrast, exposure of animals to inducers
of liver enlargement subsequent to carcinogen
treatment, according to the initiation-promotion
model employed in skin carcinogenicity ex-
periments, resulted in enhancement of carcinogenic
effectiveness. Pioneering studies in this field have
been conducted by Peraino and his associates (13-
18). At an early stage, these investigators advanced
the concept that, in analogy to the effects of phorbol
esters in skin, inducers of liver enlargement might
act as tumor promoters (13). This contention has re-
mained subject to controversy, however, following
reports that protracted treatment of rodents with
inducers of liver enlargement may cause an in-
crease in the incidence of liver tumors (19-24).
These rodents strains are characterized by a rela-
tively high incidence of "spontaneous" liver tumors,
and it is difficult to deduce from such data whether
the observed increase in the incidence of liver
tumors is due to facilitation or exacerbation of the
expression of pre-existing oncogenic potential, that
is, to tumor-promotion or, alternatively, to the
action of a weakly carcinogenic agent. The latter
concept is not supported by experiments indicating
that compounds, such as phenobarbital, DDT, diel-
drin and clofibrate possess neither genotoxic activ-
ity nor potential (25-28), but it has been argued that
current genotoxicity assays may not be appropriate
for prediction of carcinogenic hazards posed by
chemicals.
Tumorigenesis: Carcinogens
Versus Promotors
The quantitative studies of chemical carcinogene-
sis (Fig. 1) pioneered by Druckrey and associates
(29, 30), have established that clear relationships
exist between dose, time and tumor appearance.
Chemical carcinogenesis obeys the formula:
(doseXtime)n= constant and, accordingly, linear re-
gressions are obtained using logarithmic coordi-
nates; in general, negative dose is plotted versus
time. The tangent of the slope reflects the value of
n, which has been termed acceleration or rein-
forcing factor. This factor may range considerably,
from 1.1 for 4-dimethylaminoazobenzene, 2.3 for di-
ethylnitrosamine, 2.7 for N-nitrosomorpholine up to
4.0 for N-nitrosodiethanolamine. It was clear from
Druckrey's experiments-and this will be further
substantiated in this publication-that even in the
range of relatively low dose levels, there is no
detectable deviation from linearity. This evidence
indicates that carcinogenic agents cause irreversible
and cumulative effects in their target cells, and
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there are no indications for the existence of thresh-
old levels. Tumor promoters, on the other hand,
function by amplifying the impact of prior carcino-
genic insults, and it can be envisaged that such
compounds may not be operative in low dose
regions. In addition, it would seem conceivable that
tumor-promoting effects may reach a maximum at
high dose levels.
Experimental evidence in favor of this concept
can be derived from the dose-time-response charac-
teristics of TPA (12-O-tetradecanoylphorbol-13-ace-
tate)mediated enhancement of mouse skin carcino-
genesis (Hecker and Schmidt, personal communica-
tion) (Fig. 2). Negative TPA dose was plotted versus
time, and tumor response was defined as the occur-
rence of a fixed percentage of papilloma-bearing
animals. The analysis shows that in high dose level
regions, increments in TPA dose do not appear to
accelerate the appearance of tumors significantly,
suggesting that as from a particular dose level of
the promotor, oncogenic potential will become
maximally expressed. At the other end of the scale,
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the evidence clearly points towards the existence of
a threshold level for tumor-promoting action. Simi-
lar relationships for TPA can be derived from data
previously reported by Verma and Boutwell (32). It
should be possible, in principle, therefore, to dis-
criminate between tumor promoters and carcino-
gens on the basis of dose time-response studies. A
dose response analysis of the effects of phenobarbi-
tal on rat liver carcinogenesis (18) suggests similar,
although somewhat less clearcut characteristics. It
is remarkable that the acceleration of liver tumor
dieldrin
'IT (mg/kg diet)
0.1I
Q5-
50%
5-
10-
20-
50 100 200 400
-. Time (days)
FIGURE 2. Dose time-response relationships observed with
TPA (12-0-tetradecanoylphorbol-12-acetate) in 7,12-
dimethylbenzanthracene DMBA-initiated skin carcinogen-
esis in standardized experiments with NMRI mice (Hecker
and Schmidt, personal communication.
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FIGURE 3. Dose: median time to liver tumor relationship in
female CF-1 mice exposed to dieldrin (33). Arrow indicates
location of the median time to liver tumor appearance in
control animals. The dotted line indicates the median sur-
vival time of control animals. 95% confidence intervals for
treated (bars) and control animals (cross-hatched) are also
shown.
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formation in dieldrin-treated CF-1 mice (33) exhibits
a dose time-response relationship strikingly similar
to that seen with TPA. However, that this approach
may not always yield conclusive data, since tumor
manifestation periods in low dose groups may fre-
quently exceed the animal's average lifespan. This
would appear to be a general characteristic of drugs
with controversial tumorigenic properties, such as
dieldrin or DDT. This problem could be overcome,
however, by employment of a sensitive early
marker ofcarcinogenic activity.
Preneoplastic Areas as
Quantitative Early Markers of Liver
Carcinogenesis
In recent years, evidence has accumulated, that
in the case of liver, putatively preneoplastic areas
can serve this purpose (34-40) These areas, com-
monly called islets, are deficient in enzymes such as
ATPase or glucose-6-phosphatase, and may also
show glycogen storage or a positive r-glutamyl
transferase reaction, as well as considerably en-
hanced epoxide hydrolase levels (41). It is not clear
at present whether these cellular alterations are
caused by somatic mutations, and, if so, whether
these mutations are directly related to the carcino-
genic process. There is, however, a strong quantita-
tive correlation between carcinogen dose, the
extent of enzyme-deficient areas, and the sub-
sequent appearance of liver tumors (10, 35, 42). The
development of an arbitrarily defined extent of
ATPase-deficient areas in livers of rats continuously
treated with various levels of diethylnitrosamine
was found to show a dose-time-response relationship
with characteristics identical to that observed for
the induction of liver tumors (Fig. 4). This quantita-
tive correlation has recently been confirmed for N-
nitrosomorpholine (Fig. 4). These studies have also
provided evidence for the actual number of critical
events, also referred to as hits, that must occur
before ATPase deficiency becomes phenotypically
manifest. To this end, a mathematical model was de-
veloped which takes into account parameters such
as the number of susceptible liver cells, the number
of critical genes per cell, the risk per unit carcino-
gen dose for an intact critical gene to be hit and the
minimum number of hits required for induction of
islet cells (43). A comparison of the expected curves
for varying numbers of hits with the actual number
of islets observed after exposure of rats to in-
creasing total doses of diethylnitrosamine (constant
dose level administered for periods up to 6 weeks)
revealed that experimental results are consistent
with the assumption that a minimum of two hits is
001
005
010
050-
10
20
40
NNM Dose
(mg/kg/day)
Iqj/
I01%
,1%
TD50
l /
/ . f *
I' l
100 200 500 1000
Time (days)
1% 001 DENA Dose
(mg/kg/day)
005
01
05 i/
! L/
II
10 50 100 500 1000
Time (days)
FIGURE 4. Dose time-response relationship for the induction of
defined volumes of preneoplastic islets in rat liver by N-ni-
trosomorpholine (NNM) and by diethylnitrosamine
(DENA) and its quantitative correlation with the induction
of liver tumors. Adult female Lewis rats were continu-
ously exposed to the indicated levels of NNM and DENA.
For every treatment group, the exposure time required
for the induction of 0.1 and 1.0% preneoplastic areas was
determined on the basis of quantitative analyses of the
preneoplastic response in a total of 18 animals, killed at
different time intervals. These time periods were recorded
versus dose in a double logarithmic plot and compared
with the dose-time-response relationship observed for the
induction of 50% liver tumor mortality (TD50) (based on ob-
servations in 12 animals/treatment). The parallel lines indi-
cate an identical dose-time-response dependency, i.e.,
(dose) (time)n = constant.
required for the expression of the preneoplastic cell
phenotype (Fig. 5). Results in support of this con-
cept have been obtained from chronic treatment
studies with N-nitrosomorpholine at various levels
of exposure. The assumption that two critical hits
are required for enzyme deficiency is consistent
with the observed time-response relationship for
islet induction in N-nitrosomorpholine hepatocarci-
nogenesis (Fig. 6). These data indicate that islet
number is related to exposure time by a power of 2.
In contrast, dose-islet number relationships show a
slope characteristic of a one-hit mechanism. This lat-
ter phenomenon was also observed previously by
Emmelot and Scherer (35). This evidence suggests
that only the first hit is carcinogen-dependent,
whereas the second hit, which leads to phenotypical
manifestation of enzyme deficiency, would seem to
be independent of further carcinogen treatment and
caused by a time-dependent event.
Initiation and Promotion of Liver
Carcinogenesis
These considerations explain the characteristics of
islet formation following cessation of carcinogen
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FIGURE 5. Multi-hit model for the induction of ATP-ase defi-
cient cell clones in rat liver by carcinogens (43). The model
equation is:
E(I/D)= N[X (8)(i - e -)i (e-AD)fni]
where E(I, D) = expected number of ATP-ase deficient
cell islets (I) per unit volume of liver tissue, at total carcin-
ogen dose D, N = total number of susceptible liver
cells/unit volume, k = minimum number of hits required
for expression of islet cell phenotype, n = total number of
ATP-ase relevant gene loci per liver cell, A = probability
per carcinogen dose unit for an intact ATPase-relevant
gene locus to be hit. Expected curves were compared with
experimental results obtained in rats exposed to 5 mg di-
ethylnitrosamine (DENA)/kg BW/day for periods up to 6
weeks. Animals were killed and analyzed 6 weeks after the
end of DENA treatment. Experimental results are consis-
tent with the hypothesis that k = 2.
treatment, which is a necessary feature of initiation-
promotion studies. Following discontinuation of di-
ethylnitrosamine treatment, the number of preneo-
plastic islets continues to rise for a certain period
of time, and after having reached a maximum grad-
ually decreases until a steady-state level is estab-
lished (Fig. 7). These characteristics of the preneo-
plastic response following cessation of carcinogen
treatment have been observed by several groups
and were interpreted in various ways. The finding
that islet formation is initiated by a carcinogen-de-
pendent first hit and requires a time-dependent sec-
ond hit for its phenotypical manifestation may ex-
plain these characteristics on the premise that the
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FIGURE 6. Dose-response and time-response kinetics for the in-
duction of ATPase-deficient islets and liver in rat liver by
N-nitrosomorpholine (NNM). Female adult Lewis rats
were treated continuously with NNM at the dose levels of
10, 20, 40 and 80 ppm in drinking water (18 rats/treat-
ment). The animals were killed sequentially (two to five
animals at every time interval) and ATPase-deficient islets
were morphometrically analyzed in three liver sec-
tions/animal: (-) observed (--) extrapolated, Regression
analysis of relationship between islet number (y) and expo-
sure time (x) yielded following equations: NNM 80 ppm:
log y = - 2.242 + 2.327 log x; NNM 40 ppm: log y =
- 1.554 + 1.865 log x; NNM 20 ppm: log y = - 2.288 +
2.092 log x; NNM 10 ppm: log y = - 2.251 + 1.947 log x.
genetic changes leading to ATPase deficiency are
recessive in nature. Since the decrease in islet num-
ber usually starts after a time period similar to the
reported average lifespan of hepatocytes, it is con-
ceivable that enzyme-deficient cells are subject to
physiological turnover unless they assume a more
neo-plastic character. This turnover is likely to
include hepatocytes with nonexpressed first hits,
and this would explain the observation that no new
islets are being formed in the steady-state situation
(Fig. 7). Exposure to diethylnitrosamine-pretreated
rats, to phenobarbital results in pronounced en-
hancement of the preneoplastic response (Fig. 8).
During the initial stages of phenobarbital treat-
ment, these effects were found to be due entirely to
increases in the number of islets and not to any ac-
celeration of islet cell growth. Similar to the
changes observed in control animals, a maximum
was reached, followed by a decline, until the num-
ber of islets remained constant. Both maximum and
steady state were at considerably higher levels,
however, and occurred at an earlier stage than in
controls. This amplification of the preneoplastic re-
sponse resulted in an early appearance of an in-
creased number of islets with progressed neoplastic
characteristics. This was indicated by the frequent
islets/ cm3
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FIGURE 7. Changes in number, average and total size of ATPase-deficient islets in livers of Wistar rats following discontinuation
of diethylnitrosamine (DENA) treatment. Animals were exposed to the carcinogen for a period of 4 weeks at indicated daily
dose levels and killed sequentially (five animals/time interval) following discontinuation of DENA treatment.
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FIGURE 8: Effect of phenobarbital (PB) treatment on number
and size distribution of ATPase-deficient islets in livers of
Wistar rats pretreated with diethylnitrosamine (DENA):
(-) controls; (--) PB-treated. Adult animals were pre-
treated with a daily dose of 2 mg DENA/kg BW for 4
weeks and subsequently treated or not with phenobarbital
(dose equivalent to 75 mg/kg/day in drinking water).
Groups of five animals were killed 6, 12 and 18 weeks after
cessation of carcinogen pretreatment. Six sections per
liver were morphometrically analyzed. Islet number per
unit volume were estimated as described by Scherer et al.
(45).
appearance of cellular phenotypes, such as inter-
mediate and basophilic cells, that are characteristic
of later stages of hepatocarcinogenesis (44). At this
time, islet size distribution in phenobarbital-treated
rats showed a distinct shift to higher diameters.
These results suggest that the observed enhance-
ment of islet growth at later stages resulted from
an accelerated expression of neoplastic character,
and not from continuous stimulation of islet cell
multiplication by the promoting drug.
The intensity of the effects of phenobarbital on
the preneoplastic response was found to be depen-
dent on the level of prior initiation. In the experi-
ments shown in Figure 9, rats were pretreated with
varying doses of diethylnitrosamine, followed or not
followed by treatment with a constant dose of
phenobarbital. Phenobarbital accelerates the for-
mation of preneoplastic islets, and this suggests
that the compound may be operative by amplifying
the event leading to expression of the second time-
dependent hit. This effect was most pronounced at
the lowest level of exposure to the initiating carcin-
ogen. Phenobarbital was increasingly ineffective the
higher the level of prior initiation. This phenomenon
is also illustrated in Figure 10, which includes ef-
fects observed with animals pretreated with 4 mg/
kg diethylnitrosamine/day for 4 weeks. Similar re-
sults have been reported for the action of the classi-
cal tumor promoter TPA on DMBA-initiated skin
carcinogenesis (47).
These results suggest that, as a general phenom-
enon, tumor promotors act by increasing the impact
of the acceleration principle associated with time-
dependent events in carcinogenesis.
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FIGURE 9. Effect of phenobarbital treatment on the number of
ATPase-deficient islets in livers of rats pretreated with
different levels of diethylnitrosamine. Experimental de-
tails as in Figure 8. The data observed in rats pretreated
with 4 mg DENA/kg/day were omitted because of interfer-
ence with the other curves. For the 4 mg DENA treatment
group, control values were nearly identical to that seen in
the treatment group DENA (2 mg) + phenobarbital. Re-
sults observed in the treatment group DENA (4 mg) +
phenobarbital were slightly higher than those seen in the
DENA (8 mg) controls.
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Tumor Promotion in Liver:
Mechanism, Dose Dependency
and Toxicological Implications
Present evidence indicates that tumor promotion
in liver by drugs is somehow correlated with organ
enlargement. Effects on liver weight have been
found to reach a plateau after a certain treatment
period; in the case of phenobarbital this can usually
be seen after 1 week of treatment. It follows that if
proliferative processes are involved in tumor
promotion, intermittent drug treatment should
produce effects similar to those seen after con-
tinuous treatment. Accordingly, rats initiated with
diethylnitrosamine were treated with phenobarbital
for 1 week at 6-week intervals for a period of 18
weeks, and results were compared with those ob-
tained with rats treated continuously (Fig. 11).
Intermittent exposure to phenobarbital was found
to result in similar, if not more pronounced in-
creases in the number of preneoplastic islets in
liver. The observation that a total phenobarbital
dose of only 1/6 of that administered to continuously
treated rats may exert similar enhancing effects on
the preneoplastic response of liver sharply conflicts
with the concept that phenobarbital acts as a
weakly carcinogenic agent. However, the observa-
tion that pronounced tumor-promoting effects may
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FIGUTRE 10. Effect of phenobarbital (PB) on diethylnitrosamine
(DENA)-induced rat liver carcinogenesis: (0) DENA; (0)
DENA + PB. Experimental details as in Figure 8. Carci-
nogenic response defined as the occurrence of 1% ATPase-
deficient areas per unit liver volume. Effects of indicated
daily DENA dose levels when given continuously corre-
spond to those observed with the three levels of DENA
pretreatment (2, 4 and 8 mg/kg/day for 4 weeks). The for-
mer dose levels are calculated from division of the total
DENA dose administered by the number of days required
for the development of 1% ATPase-deficient areas per
unit liver volume (46).
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FIGURE 11. Effects of intermittent and continuous phenobarbi-
tal treatment on the number of ATPase-deficient islets in
livers of rats pretreated with diethylnitrosamine. Adult fe-
male Wistar rats were pretreated with diethylnitrosamine
(50 ppm in the drinking water, equivalent to an uptake of 5
mg/kg/day) for a period of 4 weeks. One group of carcino-
gen pretreated animals was subsequently treated continu-
ously with phenobarbital (0.1% in the drinking water) for
18 weeks, a second group received this dose level for only
1 week at 6-week intervals. The remaining animals served
as controls.
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FIGURE 12. Effect of varying doses of phenobarbital on num-
ber and total volume of ATPase-deficient islets in livers of
rats pretreated with N-nitrosomorpholine (NNM). Female
Lewis rats, weighing approximately 200 g, were pre-
treated with NNM (120 ppm in the drinking water for a
period of 7 weeks). Values indicate treatment mean (six
animals/group).
also occur as a result of intermittent drug treat-
ment could raise considerable problems in terms of
the assessment of drug safety in the human
situation.
Since the doses of phenobarbital usually em-
ployed in these animal studies exceed the thera-
peutic dose by several orders of magnitude, the as-
sessment of the relevance of phenobarbital-medi-
ated tumor promotion to humans would seem to
necessitate an evaluation of dose-response charac-
teristics. We have therefore investigated the dose-
dependency of phenobarbital-mediated tumor pro-
motion in rats (44). Quantitative analysis of number,
total volume and size distribution of ATPase-
negative and y-glutamyltransferase-positive islets
indicated that significant effects were associated
with a phenobarbital dose of 75 mg/kg only (Fig. 12).
Smaller exposure levels caused limited effects with-
in control range. None of the three phenobarbital
exposure levels caused any effect in livers of nonini-
tiated animals. These latter results constitute addi-
tional evidence to indicate that the compound is de-
void of carcinogenic activity. The dose-response
lines, when recorded as in Figure 2, showed that in
this dose region the effects approach zero. It should
be noted however, that even with a threshold dose
clearly defined in rodents on the basis of these
studies, risk assessments may not be realistic as
long as the nature of the critical cellular events and
the dose levels required to produce such effects in
humans remain obscure.
In the reported dose-response study with pheno-
barbital, induction of the microsomal mono-oxygen-
ase system was noted in all treatment groups, fol-
lowed by dose-dependent increases in liver weight.
At dose levels associated with overt tumor-
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FIGURE 13. Hepatocellular changes induced by phenobarbital.
Adult female NMRI mice were continuously treated with
phenobarbital (0.1% in the drinking water). All cytological
parameters were quantified with light microscopy on liver
sections. Ploidy histograms were measured in sections
and, additionally, in isolated liver nuclei. 3H-thymidine au-
toradiography was carried out as described by Rabes et al.
(48), DNA content of nuclei was determined by microscope
fluorimetry of Feulgen-stained material. Specific radioac-
tivity in nuclei was determined by using a Leitz micro-
scope photometer MPV (42).
promoting action, these effects were accompanied
by an increased formation of hydrogen peroxide and
superoxide anions in liver microsomes in vitro
(unpublished observations). It is interesting to note
that induction of reactive oxygen species has also
been observed in livers of rats exposed to tumor-
promoting drugs that fail to induce microsomal
enzyme systems, such as clofibrate and halothane.
The formation of reactive oxygen species is
presently discussed as a critical phenomenon in
TPA-mediated tumor promotion, since this effect
appears to be related to the stimulation of cell pro-
liferation, in particular of cellular polyploidization,
and possibly also to the induction of sister-chroma-
tide exchanges. A marked increase in hepatocellular
ploidy status is also characteristic of drug-induced
liver enlargement. Analysis of cytological
parameters revealed that in the initial stages of
liver enlargement, this phenomenon is due not only
to DNA replication and endomitosis, but also to nu-
clear fusion in binucleated liver cells (Fig. 13). Fol-
lowing adaptation of the liver to the increased
functional demands, and particularly after cessation
of drug-treatment, there is a decline in the extent of
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nuclear polyploidy associated with an increase in
the number of polynucleated cells. In the course of
this process atypical nuclear figures are frequently
observed, which may be a reflection of aberrant nu-
clear divisions. It is conceivable that changes in
hepatocellular ploidy status leading to abnormal
chromosomal redistribution could turn heterozy-
gous mutations homozygous. In this way, recessive
oncogenic information could become phenotypically
manifest (second hit). This concept provides an ex-
planation for the observed increases in the number
of islets for considerable periods of time after dis-
continuation of carcinogen treatment and for the im-
pact of tumor-promoting drugs on this process. The
accelerated progression of the neoplastic character
of islets in livers of phenobarbital-treated animals
may be similarly explained.
The induction of such critical events in rodent
liver necessitates high exposure levels of tumor-pro-
moting agents usually far in excess of the levels
used in the human situation. In this context, it is
interesting to note that epidemiological surveys
have failed to demonstrate adverse effects of
protracted phenobarbital treatment on human
health (49, 50). It remains conceivable, however, that
some tumor-promoting drugs could trigger critical
disturbances in liver cells at dose levels ap-
proaching those used in human therapy (51).
These considerations may have important gen-
eral implications for the design and interpretation
of animal carcinogenicity tests. Such experiments
must address the question whether tumorigenic
effects are due to the action of a carcinogenic agent,
or to facilitation of the expression of a pre-existing
endogenous, viral or environmental oncogenic
factor. Since the effects of promotors would seem to
be reversible and nonexistent below threshold
levels, the risks associated with these compounds
should be assessed on the basis of exposure levels
relevant to man.
This paper is dedicated to Professor 0. Westphal on the
occasion of his 70th birthday.
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